Journal of Cancer Research and Pharmacology (eISSN: 3115-798X) (J Cancer Res Pharmacol) is an international, peer-reviewed, open-access journal published quarterly (4 issues per year). The journal is dedicated to advancing knowledge in oncology and pharmacological sciences, with a focus on innovative research, therapeutic developments, and multidisciplinary approaches to cancer treatment.
J Cancer Res Pharmacol serves as a global platform for researchers, clinicians, and pharmacologists to share cutting-edge findings, critical reviews, and perspectives that bridge the gap between laboratory research and clinical practice.
Key topics covered include:
By fostering collaboration and disseminating high-quality research, the journal aims to accelerate progress in cancer therapeutics and improve patient outcomes worldwide.
Owner and Publisher
Fargostar Salamat Sialk Asia
Publication Frequency
Quarterly (4 issues per year)
Open Access Policy
Since making research freely available supports a greater global exchange of knowledge, "Journal of Cancer Research and Pharmacology" provides immediate open access to its content.
Repository Policy
"Journal of Cancer Research and Pharmacology" has a policy that permits authors to deposit all versions of their article in any institution or other repository of their choice without embargo.
Archiving
This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration.
Editorial Independence
The editor in chief makes the final decision regarding the publication or rejection of the submitted articles without interference from its owner or economic interests.
Plagiarism policy
When an author tries to present the work of someone else as his or her own, it is called plagiarism. In addition, when an author uses a considerable portion of his or her own previously published work in a new one without properly citing the reference, it is called a duplicate publication sometimes also referred to as self-plagiarism. This may range from publishing the same article in another journal to 'salami-slicing', which is data segmentation, to adding little new data to the previous article.
The editorial team/reviewers of "Journal of Cancer Research and Pharmacology" will check the submitted manuscripts for plagiarism twice (once after submission and once before publication) using available plagiarism detection software such as iThenticate. If suspected plagiarism is found in an article either before (by reviewers or editorial team) or after (by readers) publication, Journal of Cancer Research and Pharmacology will act according to COPE’s code of conduct and flowcharts.
Article Withdrawal
Author(s) should note that they can withdraw their articles before being sent for peer review or when they are returned to them for making changes (minor or major revisions required), and not when they are under peer review. Unless that round of peer review (and not the total duration) for the article has exceeded the maximum duration of the peer review process stated on the website (4 weeks).
Articles can only be withdrawn before their acceptance, except in cases that contain errors or have been accidentally submitted twice. Occasionally, articles may represent infringements of professional ethical codes, such as multiple submissions, bogus claims of authorship, plagiarism, fraudulent use of data, or the like.
Articles that include errors, or are duplicates of or very similar to other published article(s) or are determined to violate the journals’ publishing ethics guidelines in the view of the editors, may be withdrawn.
For this purpose, a withdrawal letter must be emailed to the editorial office indicating the decision to withdraw and explaining the reason for withdrawal signed by the corresponding author and the submitting individuals’ signature.